Coloplast's Financial Performance in Q1 2024/25
Coloplast is pleased to present its interim financial results for the first quarter of 2024/25, which demonstrates robust performance and consistent growth across several business divisions. From October 1, 2024, to December 31, 2024, the company achieved an impressive 8% organic growth while maintaining an EBIT margin of 27%.
Revenue Highlights and Performance Drivers
The reported revenue in DKK saw a 6% increase, although the figures were slightly dampened by the divestment of the Skin Care segment and adverse currency impacts. A closer look at organic growth rates reveals that Ostomy Care and Continence Care both reported 7% growth, while Voice and Respiratory Care led the charge with an impressive 11% increase. Advanced Wound Care also excelled, achieving a 12% growth rate.
The Chronic Care division continues to show promise with notable contributions from both Europe and the U.S., whereas emerging markets faced challenges due to a high baseline last year. The launch of the Luja™ intermittent catheter platform significantly bolstered growth in Continence Care.
Operational Adjustments and Strategic Moves
Coloplast made a strategic move in December by divesting its Skin Care portfolio, aiming to enhance operational efficiency and profitability within Advanced Wound Care. The Advanced Wound Dressings segment witnessed a solid 6% growth, primarily driven by strong performance in European markets.
Kerecis, an important player in Coloplast's portfolio, reported a remarkable 32% growth, reflecting successful market share gains. The company also announced that Kerecis was included in the final Local Coverage Determination policy for Diabetic Foot Ulcers, with an implementation date set for April 2025.
Challenges and Market Adjustments
While the Interventional Urology sector faced setbacks from a voluntary product recall within the Bladder Health and Surgery category, this was offset by solid performances in Endourology. The expected impact of the recall on Q2 sales is approximately DKK 15 million. Fortunately, sales for the affected products are anticipated to resume in February.
Financial Metrics and Future Guidance
EBIT for the quarter amounted to DKK 1,912 million, marking a 5% year-on-year increase. However, the EBIT margin experienced a slight decline from 28% to 27%, largely due to elevated commercial and logistical expenses. This quarter included extraordinary costs related to the establishment of the U.S. distribution center, alongside currency fluctuations.
Analyzing tax implications reveals that while the ordinary tax rate stood at 22%, the effective tax rate spiked to 41% due to an extraordinary expense relating to Kerecis’s Intellectual Property transfer from Iceland to Denmark. This strategic move is projected to have ramifications for cash flows, with tax payments in Iceland anticipated to impact fiscal year 2026/27, balanced by reduced tax obligations in Denmark starting fiscal year 2024/25.
Outlook for FY 2024/25
Coloplast maintains its guidance for FY 2024/25 with expectations of 8-9% organic growth and an EBIT margin before special items around 28%. The forecast continues to assume strong underlying momentum, a 1%-point addition from Kerecis, and improved growth within Interventional Urology in the second half of the year.
Reported growth in DKK is now anticipated to be around 7%, a slight adjustment from the previous guidance of 8-9%. This adjustment incorporates an approximately 1.5%-point negative impact from the Skin Care divestment over ten months and a neutral expected impact from currencies.
Capital expenditures are projected to stay at around DKK 1.4 billion, while the ordinary tax rate is expected to remain near 22%. Nonetheless, due to the extraordinary nature of the Kerecis IP transfer, the effective tax rate is now estimated around 40%. Long-term tax expectations remain unchanged at approximately 23%.
Concluding Remarks from Leadership
President & CEO Kristian Villumsen expressed optimism about the company's strong start to fiscal year 2024/25, highlighting the significant contribution of the Luja™ platform in Chronic Care. He remarked, “Our two recent acquisitions, Atos Medical and Kerecis, continue to show double-digit growth, enhancing the standard of care for numerous individuals with intimate health needs.”
For further information, please reach out to our Investor Relations team or refer to our contact details listed below.
Frequently Asked Questions
What was Coloplast's reported EBIT for Q1 2024/25?
Coloplast reported an EBIT of DKK 1,912 million, which is a 5% increase compared to the previous year.
How did Coloplast's organic growth perform across different segments?
The company saw varied performance: Ostomy Care and Continence Care both achieved 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12%, and Interventional Urology grew by 1%.
What strategic move did Coloplast take regarding its Skin Care portfolio?
Coloplast divested its Skin Care portfolio in December to streamline operations and enhance the profitability of its Advanced Wound Care segment.
What effect did the Kerecis IP transfer have on Coloplast's tax rates?
The transfer resulted in an effective tax rate of 41% for Q1 due to extraordinary expenses, though long-term expectations remain unchanged around 23%.
What is Coloplast's organic growth guidance for FY 2024/25?
Coloplast maintains its organic growth guidance at 8-9% for FY 2024/25, assuming continued strong momentum and a positive contribution from Kerecis.
